



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/024,632	12/19/2001	Steve Sichuan He	38-21(51837)B	8916
75	90 01/04/2006		EXAM	INER
Lawrence M. l	Lavin, Jr.		BAUM, S	TUART F
Patent Departme	ent, E2NA			
Monsanto Comp	pany		ART UNIT	PAPER NUMBER
800 N. Lindberg			1638	
St. Louis, MO			DATE MAILED: 01/04/2006	6

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/024,632	HE ET AL.
Office Action Summary	Examiner	Art Unit
	Stuart F. Baum	1638
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
 1) Responsive to communication(s) filed on 11 Oc 2a) This action is FINAL. 2b) This 3) Since this application is in condition for allowar 	action is non-final.	osecution as to the merits is
closed in accordance with the practice under E	·	
Disposition of Claims		
4) ☐ Claim(s) 3-6 is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 3-5 is/are rejected. 7) ☐ Claim(s) 6 is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or		
Application Papers		
9) The specification is objected to by the Examine 10) The drawing(s) filed on 12/19/01, 5/6/02 is/are: Applicant may not request that any objection to the constant drawing sheet(s) including the correction of the order of t	a)⊠ accepted or b)⊡ objected drawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Applicati ity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Profitographic Retail Provides Review (PTO 048)	4) Interview Summary Paper No(s)/Mail Da	
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 		atent Application (PTO-152)

DETAILED ACTION

1. In view of the appeal brief filed on 10/11/2005, PROSECUTION IS HEREBY REOPENED. New grounds of rejection are set forth below.

To avoid abandonment of the application, appellant must exercise one of the following two options:

- (1) file a reply under 37 CFR 1.111 (if this Office action is non-final) or a reply under 37 CFR 1.113 (if this Office action is final); or,
- (2) initiate a new appeal by filing a notice of appeal under 37 CFR 41.31 followed by an appeal brief under 37 CFR 41.37. The previously paid notice of appeal fee and appeal brief fee can be applied to the new appeal. If, however, the appeal fees set forth in 37 CFR 41.20 have been increased since they were previously paid, then appellant must pay the difference between the increased fees and the amount previously paid.

A Supervisory Patent Examiner (SPE) has approved of reopening prosecution by signing

below:

Anne Marie Grunberg

Supervisory Patent Examiner

Art Unit 1638 and 1661

- 2. Claims 3-6, including SEQ ID NO:2 are pending and are examined in the present office action.
- 3. The Office acknowledges Applicants' remarks in the Appeal Brief filed 10/11/2005, that address the written description and enablement rejections from the final office action mailed

11/19/2004. Because the present written description, enablement and 102 rejections address new issues, not previously before articulated, the Office holds off from addressing the remarks, and will do so in the next office action, if appropriate.

Claim Objection

4. Claims 6 is objected to for omitting the word "acid" after the word "amino". Correction is requested.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

5. Claim 4 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 4 is indefinite for reciting "stringent conditions". Applicants do not explicitly define "stringent conditions" in the claims or in the specification (see page 17 of specification, lines 14-29). Applicants only give examples of possible stringent hybridization conditions. Therefore, the metes and bounds of "stringent conditions" have not been disclosed.

Written Description

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it

pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 3-5 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are drawn to an isolated nucleic acid molecule comprising a nucleic acid sequence which encodes a polypeptide having an amino acid sequence that is substantially identical to a sequence of SEQ ID NO:2, an isolated nucleic acid molecule comprising a nucleotide sequence or its complement, which hybridizes under stringent conditions to a nucleic acid molecule which encodes a protein with substantial identity to SEQ ID NO:2, or an isolated nucleic acid sequence which encodes an amino acid sequence comprising SEQ ID NO:2 containing conservative amino acid substitutions.

Applicants define "substantially identical" and "substantial identity" to mean that one amino acid or nucleotide sequence has 60% sequence identity when compared to a reference amino acid or nucleotide sequence (page 15 of specification, lines 10-18).

The Office interprets "a sequence of SEQ ID NO:2" to read on a large number of sequences because "a sequence of SEQ ID NO:2" reads on any two amino acids of SEQ ID NO:2.

Because Applicants do not explicitly define "stringent conditions" in the claims or in the specification (see page 17 of specification, lines 14-29) as noted above, the Office interprets "stringent conditions" to mean low stringency conditions.

Applicants define "conservative amino acid substitutions" to mean substitutions of one or more amino acids in a native amino acid sequence with another amino acid(s) having similar side chains (page 15 of specification, lines 28-29).

Applicants isolated a cDNA clone from soybean, SEQ ID NO:1, that encodes SEQ ID NO:2, that shares sequence identity with the *Arabidopsis* ANT protein (pages 47-49, Example 1). Applicants disclose that SEQ ID NO:2 contains two AP2 DNA binding domains that share homology with the *Arabidopsis* ANT polypeptide, four conserved segments were identified in the N-terminal before the AP2 DNA binding domains, suggesting a possible functional role, and the C-terminal sequence of SEQ ID NO:2 bears little homology with that of the *Arabidopsis* ANT protein but does share conserved segments with another ANT-like clone isolated from soybean. Applicants suggest that these C-terminal segments may perform additional or distinguishable functions from the *Arabidopsis* ANT polypeptide (page 49, 2nd full paragraph).

The Applicants do not identify essential regions of SEQ ID NO:2 encoded by SEQ ID NO:1, nor do Applicants describe any polynucleotide sequence that encodes any protein comprising any two amino acids of SEQ ID NO:2, nor any polynucleotide sequence that encodes a protein exhibiting 60% amino acid identity with SEQ ID NO:2, nor any polynucleotide sequences that hybridize under low stringency conditions to another nucleotide sequence that encodes a protein having 60% amino acid identity to SEQ ID NO:2 nor any polynucleotide sequence encoding an amino acid sequence comprising SEQ ID NO:2 in which all amino acids have been substituted with conservative amino acids, and wherein the encoded protein has the same function/activity as the protein encoded by SEQ ID NO:1.

The Federal Circuit has recently clarified the application of the written description requirement to inventions in the field of biotechnology. See University of California v. Eli Lilly and Co., 119 F.3d 1559, 1568, 43 USPQ2d 1398, 1406 (Fed. Cir. 1997). In summary, the court stated that a written description of an invention requires a precise definition, one that defines the structural features of the chemical genus that distinguishes it from other chemical structures. A definition by function does not suffice to define the genus because it is only an indication of what the gene does, rather than what it is. The court goes on to say, "A description of a genus of cDNAs may be achieved by means of a recitation of a representative number of cDNAs, defined by nucleotide sequence, falling within the scope of the genus or of a recitation of structural features common to members of the genus, which features constitute a substantial portion of the genus." See University of California v. Eli Lilly and Co., 119 F.3d 1559; 43 USPQ2d 1398, 1406 (Fed. Cir. 1997).

Applicants fail to describe a representative number of polynucleotide sequences encoding SEQ ID NO:2 falling within the scope of the claimed genus of polynucleotides, comprising sequences that encode polypeptides that comprise any two amino acids of SEQ ID NO:2, or encode a polypeptide exhibiting 60% amino acid identity with SEQ ID NO:2, or polynucleotides that hybridize under low stringency conditions with another polynucleotide that encodes a polypeptide exhibiting 60% sequence identity with SEQ ID NO:2, or a polynucleotide which encodes a polypeptide comprising SEQ ID NO:2 in which all of the amino acids have been substituted with conservative amino acids, and wherein any of the encoded proteins have the same function/activity as the protein encoded by SEQ ID NO:1. Applicants only describe a single cDNA of SEQ ID NO:1 encoding SEQ ID NO:2. Furthermore, Applicants fail to describe

Application/Control Number: 10/024,632 Page 7

Art Unit: 1638

structural features common to members of the claimed genus of polynucleotides. Hence, Applicants fail to meet either prong of the two-prong test set forth by *Eli Lilly*. Furthermore, given the lack of description of the necessary elements essential for the protein of SEQ ID NO:2, it remains unclear what features identify the genus of nucleic acid sequences encoding the claimed genus of polypeptides. Since the genus of proteins of SEQ ID NO:2 has not been described by specific structural features, the specification fails to provide an adequate written description to support the breath of the claims.

Scope of Enablement

7. Claims 3-5 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for an isolated nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence comprising SEQ ID NO:2, does not reasonably provide enablement for a nucleotide sequence or its complement, which encode a polypeptide having an amino acid sequence that is substantially identical to a sequence of SEQ ID NO:2, an isolated nucleic acid molecule comprising a nucleotide sequence or its complement, which can hybridize under stringent conditions to a nucleic acid sequence which can encode a protein with substantial identity to SEQ ID NO:2, or an isolated nucleic acid sequence which encodes an amino acid sequence comprising SEQ ID NO:2 containing conservative amino acid substitutions. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

The claimed invention is not supported by an enabling disclosure taking into account the Wands factors. In re Wands, 858/F.2d 731, 8 USPQ2d 1400 (Fed. Cir. 1988). In re Wands lists a number of factors for determining whether or not undue experimentation would be required by one skilled in the art to make and/or use the invention. These factors are: the quantity of experimentation necessary, the amount of direction or guidance presented, the presence or absence of working examples of the invention, the nature of the invention, the state of the prior art, the relative skill of those in the art, the predictability or unpredictability of the art, and the breadth of the claim.

The claims are drawn to an isolated nucleic acid molecule comprising a nucleotide sequence or its complement, which encode a polypeptide having an amino acid sequence that is substantially identical to a sequence of SEQ ID NO:2, an isolated nucleic acid molecule comprising a nucleotide sequence or its complement, which can hybridize under stringent conditions to a nucleic acid sequence which can encode a protein with substantial identity to SEQ ID NO:2, or an isolated nucleic acid sequence which encodes an amino acid sequence comprising SEQ ID NO:2 containing conservative amino acid substitutions.

Applicants define "substantially identical" and "substantial identity" to mean that one amino acid or nucleotide sequence has 60% sequence identity when compared to a reference amino acid or nucleotide sequence (page 15 of specification, lines 10-18).

The Office interprets "a sequence of SEQ ID NO:2" to read on a large number of sequences because "a sequence of SEQ ID NO:2" reads on any two amino acids of SEQ ID NO:2.

Application/Control Number: 10/024,632

Art Unit: 1638

Because Applicants do not explicitly define "stringent conditions" in the claims or in the specification (see page 17 of specification, lines 14-29) as noted above, the Office interprets "stringent conditions" to mean low stringency conditions.

Applicants define "conservative amino acid substitutions" to mean substitutions of one or more amino acids in a native amino acid sequence with another amino acid(s) having similar side chains (page 15 of specification, lines 28-29).

Applicants isolated a cDNA clone from soybean, SEQ ID NO:1, that encodes SEQ ID NO:2, that shares sequence identity with the *Arabidopsis* ANT protein (pages 47-49, Example 1). Applicants disclose that SEQ ID NO:2 contains two AP2 DNA binding domains that share homology with the *Arabidopsis* ANT polypeptide, four conserved segments were identified in the N-terminal before the AP2 DNA binding domains, suggesting a possible functional role, and the C-terminal sequence of SEQ ID NO:2 bears little homology with that of the *Arabidopsis* ANT protein but does share conserved segments with another ANT-like clone isolated from soybean. Applicants suggest that these C-terminal segments may perform additional or distinguishable functions from the *Arabidopsis* ANT polypeptide (page 49, 2nd full paragraph). Applicants transformed *Arabidopsis* with SEQ ID NO:1 operably linked to the 35S promoter to produce plants with increased growth and biomass of the roots (page 72, 1st paragraph), increased floral size and increased seed size (page 73, Examples 28 and 29).

Applicants are not enabled for the full scope of the broadly claimed invention.

Applicants have not disclosed any nucleotide sequence that encodes a protein exhibiting 60% amino acid identity with SEQ ID NO:2 or with any sequence disclosed in SEQ ID NO:2 and can be used to transform a plant in which the resultant transgenic plant phenotype is the same as a

plant transformed with a nucleic acid encoding SEQ ID NO:2. Applicants have also not disclosed a nucleotide sequence or its complement, which hybridizes under low stringency conditions to a nucleotide sequence encoding a protein exhibiting 60% amino acid identity with SEQ ID NO:2, and wherein a plant transformed with said nucleotide sequence results in a plant phenotype that is the same as a plant transformed with a nucleic acid encoding SEQ ID NO:2. And lastly, Applicants have not disclosed a nucleic acid sequence which encodes a protein comprising SEQ ID NO:2 in which every amino acid has been substituted with a corresponding conservative amino acid, and wherein a plant transformed with said nucleic acid exhibits a phenotype that is the same as a plant transformed with a nucleic acid encoding SEQ ID NO:2.

The state-of-the-art is such that one of skill in the art cannot predict which nucleic acids that encode a polypeptide with substantial identity to SEQ ID NO:2 will encode a protein with the same activity as a protein comprising the amino acid sequence of SEQ ID NO:2. The prediction of protein structure from sequence data and, in turn, utilizing predicted structural determinations to ascertain functional aspects of the protein, is extremely complex, and the positions within the protein's sequence where amino acid substitutions can be made with a reasonable expectation of maintaining function are limited (Bowie et al, Science 247:1306-1310, 1990, see especially page 1306). Proteins may be sensitive to alterations in even a single amino acid in a sequence. For example, the replacement of a glycine residue located within the START domain of either the PHABULOSA or PHAVOLUTA protein receptor with either an alanine or aspartic acid residue, alters the sterol/lipid binding domain (McConnell et al, Nature 411 (6838):709-713, 2001, see especially page 710, left column, 2nd paragraph).



Making "conservative" substitutions (e.g., substituting one polar amino acid for another, or one acidic one for another) does not produce predictable results. Lazar et al (1988, Mol. Cell. Biol. 8:1247-1252) showed that the "conservative" substitution of glutamic acid for aspartic acid at position 47 reduced biological function of transforming growth factor alpha while "nonconservative" substitutions with alanine or asparagine had no effect (abstract). Similarly, Hill et al (1998, Biochem. Biophys. Res. Comm. 244:573-577) teach when three histidines that are maintained in ADP-glucose pyrophosphorylase across several species are substituted with the "nonconservative" amino acid glutamine, there is little effect on enzyme activity, while the substitution of one of those histidines with the "conservative" amino acid arginine drastically reduced enzyme activity (see Table 1). All these mutated proteins, would produce a polypeptide with substantial identity with SEQ ID NO:2. The nucleic acids encoding all these mutated proteins, however, would hybridize under stringent conditions to the nucleic acids encoding the original protein.

Applicants' claims are drawn to nucleic acid sequences that hybridize to a nucleic acid sequence encoding a polypeptide with substantial identity to SEQ ID NO:2, but the state-of-the-art teaches isolating DNA fragments using stringent hybridization conditions, does not always select for DNA fragments whose contiguous nucleotide sequence is the same or nearly the same as the probe. Fourgoux-Nicol et al (1999, Plant Molecular Biology 40:857-872) teach the isolation of a 674bp fragment using a 497bp probe incorporating stringent hybridization conditions comprising three consecutive 30 minute rinses in 2X, 1X and 0.1X SSC with 0.1% SDS at 65°C (page 859, left column, 2nd paragraph). Fourgoux-Nicol et al also teach that the probe and isolated DNA fragment exhibited a number of sequence differences comprising a 99bp

insertion and a single nucleotide gap, while the DNA fragment contained 2 single nucleotide gaps and together the fragments contained 27 nucleotide mismatches. Taking into account the insertions, gaps and mismatches, the longest stretch of contiguous nucleotides to which the probe could hybridize consisted of 93bp of DNA (page 862, Figure 2).

Given the Office's interpretation of "a sequence of SEQ ID NO:2" as discussed above, the state-of-the-art teaches transforming a plant with a nucleic acid sequence that encodes a polypeptide that is substantially identical to any sequence of SEQ ID NO:2 produces unexpected results. Kano-Murakami et al (1993, FEBS 334:365-368) teach introducing the *Oryza sativa* homeobox 1 (OSH1) gene into tobacco. OSH1 is a rice homologue of the *Knotted-1* homeobox gene from maize and would be encompassed by Applicant's broad claim language, as discussed above. Kano-Murakami et al teach transgenic tobacco plants comprising the OSH1 gene display a "range of phenotypes which include abnormalities in leaf and petal shape as well as stem height and number" (page 365, right column, 1st paragraph).

Applicants have not disclosed how one makes or isolates any of the sequences that are encompassed by Applicants' broad claims. Applicants have not taught which regions of the respective polynucleotides can be used to amplify any of said polynucleotides or which regions can be used as a probe to isolate any of said polynucleotide sequences.

In the absence of guidance, undue trial and error experimentation would be required for one of ordinary skill in the art to screen through the multitude of non-exemplified sequences, either by selecting random pieces of DNA as probes or by designing primers to undisclosed regions of SEQ ID NO:2 and isolating or amplifying fragments, subcloning the fragments, producing expression vectors and transforming plants therewith, in order to identify those, if any,

that when over-expressed could produce plants with a morphology as specified by Applicant and encode a protein with substantial identity to a sequence of SEQ ID NO:2, or wherein the nucleotide sequence or its complement can hybridizes under low stringency conditions to a nucleotide sequence encoding a protein exhibiting 60% amino acid identity with SEQ ID NO:2, or wherein the nucleic acid sequence can encodes a protein comprising SEQ ID NO:2 in which every amino acid has been substituted with a corresponding conservative amino acid.

Therefore, given the breadth of the claims; the lack of guidance and examples; the unpredictability in the art; and the state-of-the-art as discussed above, undue experimentation would be required to practice the claimed invention, and therefore the invention is not enabled.

Claim Rejections - 35 USC § 102

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

8. Claims 3-5 are rejected under 35 U.S.C. 102(b) as being anticipated by Elliott et al (1996, The Plant Cell 8:155-168).

The claims are drawn to an isolated nucleic acid molecule comprising a nucleotide sequence, or its complement which encodes a polypeptide having an amino acid sequence that is substantially identical to a sequence of SEQ ID NO:2, an isolated nucleic acid molecule comprising a nucleotide sequence, or its complement, which hybridizes under stringent conditions to a nucleic acid molecule which encodes a protein with substantial identity to SEQ ID NO:2, or an isolated nucleic acid sequence which encodes an amino acid sequence comprising SEQ ID NO:2 containing conservative amino acid substitutions.





Applicants define "substantially identical" and "substantial identity" to mean that one amino acid or nucleotide sequence has 60% sequence identity when compared to a reference amino acid or nucleotide sequence (page 15 of specification, lines 10-18).

The Office interprets "a sequence of SEQ ID NO:2" to read on a large number of sequences because "a sequence of SEQ ID NO:2" reads on any two amino acids of SEQ ID NO:2.

Because Applicants do not explicitly define "stringent conditions" in the claims or in the specification (see page 17 of specification, lines 14-29) as noted above, the Office interprets "stringent conditions" to mean low stringency conditions.

Applicants define "conservative amino acid substitutions" to mean substitutions of one or more amino acids in a native amino acid sequence with another amino acid(s) having similar side chains (page 15 of specification, lines 28-29).

Elliott et al teach a nucleic acid sequence that encodes the Arabidopsis

AINTEGUMENTA (ANT) protein that exhibits 38% sequence identity to Applicants' SEQ ID

NO:2 (See enclosed sequence search results). The sequence of Elliot et al encodes a protein that
is substantially identical to any sequence of SEQ ID NO:2, given that the encoded protein
comprises at least any two amino acid residues that are found in Applicants' encoded protein.

The sequence of Elliot et al would hybridize under low stringency conditions to a nucleic acid
sequence encoding a protein exhibiting 60% amino acid identity to SEQ ID NO:2. Lastly, the
Office considers the nucleic acid sequence of Elliot et al to encode a polypeptide comprising
SEQ ID NO:2 containing conservative amino acid substitutions because the Office considers all
amino acids that are not 100% identical to the respective amino acids in applicants' SEQ ID

Application/Control Number: 10/024,632 Page 15

Art Unit: 1638

NO:2, to be amino acids comprising similar side chains, based on applicants' definition of "conservative amino acid substitutions" as disclosed above. And as such, Elliot et al anticipate the claimed invention.

- 9. Claim 6 is deemed free of the prior art, given the failure of the prior art to teach or reasonably suggest an isolated nucleic acid sequence encoding the amino acid sequence comprising SEQ ID NO:2.
- 10. Claim 6 is objected to, but would be allowable if rewritten to correct the deficiencies as discussed above.
- 11. Claims 3-5 are not allowed.
- 12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stuart F. Baum whose telephone number is 571-272-0792. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached at 571-272-0975. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/024,632 Page 16

Art Unit: 1638

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is 571-272-1600.

Boun

Stuart F. Baum Ph.D.

Patent Examiner Art Unit 1638

December 19, 2005

```
SSHSNHHODSSPRVEDFPGTHANTSHKRAMDLSLDSLFYNTTHEPNTTTNFORFFSP
POTRÄHERETANYGNDPSLTHGGSFNVGYYGBPOQSLSLSMSPGSQSSCLTGSHÄHOO
NONQNHOSONHOOLSEALVETSVGFPTTTMAAAKGGRGOEDVIVVVGOKOLVHRKSLDT
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          123 ---LeuSerLeuAspSerileTyrTyrAsnSerGlnAsnAlaGluAlaGlnProAsnArg 141
SSAATSSSSVPPQLVVGDNTSNFGVCYGSNPNGGIYSHMSVMPLRSDGSLCLMBALNR
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           142 AspleuLeuSerglnProPhe-----ArgGlnGlnGlyHisMetSerValGln 157
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     84 GluhlaheulysArgSerGlnThrGlnValMetValProThrSerSerProLysLeuGlu 103
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        329 dalacricicalchartartererecenterereagaricalcicalageresia 388
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            104 AgpPheLeuGlyGlyAlaThrMetGlyThrHisGluTyrGlySerHisGluArgGly--- 122
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                488 ACTACAAACTTTCAAGAGTTCTTTAGCTTCCCTCAAACCAGAACCAT----- 535
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               158 ThrHisProTyrTyrSerGlyLeuAlaCysHisGlyLeuTyrGlnAlaProLeuGluGlu 177
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   178 GluThrThrLysGluThrHisValSerAspCysSerSerLeuMetProGlnMetThrGlu 197
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    542 GANACT-----AGANATTACGGGNATGAC-------CCTAGTTTGACACAT 580
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        GlyLeuLysAsnTrpValAlaProThrArgGluPheSerThrHisGlnGlnValLeuGlu 217
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ę,
                                                                                                                                                                                                                                                                                                                                                                                                                                                                 1 MetLysArgileAsnGluSerAsnAsnThrAspAspGlyAsnAsnHisAsnTrpLeuGly 20
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 38 AIGAGICITITIGIGALAATGAIGAIAATAATGAIGGGAGAGAGGGGGGGGG
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    30 ---------GlualaThrSerAlaAlaThrValProThrThrPheTyzMet
                                                                                                                                                                                                                                                                                                          Length:
Matches:
Conservative:
Mismatches:
Indels:
                                                                                                                                                                                                                                                                                                                                                                                                                              US-10-024-632-2 (1-663) x ATU41339 (1-1905)
                                                                                                                                                                                                                                                                                                        6.666-81
1328.00
52.84%
43.27%
37.92%
                                                                                                                                                                                                                                                                                                                                  Percent Similarity:
Best Local Similarity:
Query Match:
DB:
                                                                                                                                                    misc_feature
                                                                                                                                                                                                       misc_feature
                                                                                                                                                                                                                                                                                         Alignment Scores:
                                                                                                                                                                                                                                                                                                              200
                                                                                                                                                                                                                                                          ORIGIN
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ద
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              å
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       8 6
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   셤
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     셤
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ò
                                                                                                                                                                                                                                                                                                                                                                                                                                                               ઠે
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            g
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ò
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ઠે
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           징
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ò
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            g
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ઠે
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ठे
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    õ
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ò
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          유
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              원
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ò
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               8
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ò
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        /gene="AINTEGUMENTA"
/gene="similar to APETALA2 protein encoded by GenBank
Accession Number U12546"
/codon start=1
/producin_id="AMB17364.1"
/brotein_id="AMB17364.1"
/db_xref="Gi1244708"
/translation="MKSPCDNDDNNHSNTTNLGFSLSSNW#NWGGRGGREAIYSSST
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Arabidopsis thalians (thale cress)
Arabidopsis thalians
Bukaryotes thalians
Bukaryotes, Viridiplantae, Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Wagnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicacese; Arabidopsis.
1 (bases I to 1905)
Bliott.R.C. Betzner, A.S., Huttner, E., Oakes, M.P., Tucker, W.Q.,
Gerentes, D., Perez, P. and Smyth, D.R.,
AINTEGUMENTA, an APETALA-like gene of Arabidopsis with pleiotropic
roles in ownle development and floral organ growth
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ATU41339 1905 bp mRNA linear PLN 23-OCT-1996
Arabidopsis thaliana ANT (AINTEGUMENTA) mRNA, complete Cds.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 2 (Dases 1 to 1905)
Smyth, D.R.
Submitted (27-NOV-1995) David Smyth, Genetics and Dev. Biology,
Submitted (27-NOV-1995) David Smyth, Genetics and Dev. Biology,
Monash University, Wellington Road, Clayton, VIC 3168, Australia
Location/Qualifiers
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    /organism="Arabidopsis thaliana"
/mol_type="mxNN"
/strain="Landsberg erecta"
/db_xref="taxon:3702"
/chromosome="4"
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          /map="between spt and cer-9"
/tissue type="flower; ovule"
1. .1905
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             /gene="AINTEGUMENTA"
38
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         U41339
U41339.1 GI:1244707
```

DEFINITION ACCESSION VERSION KEYWORDS SOURCE ORGANISM

REGULT 8 ATU41339 REFERENCE AUTHORS

TITLE

JOURNAL MEDLINE PUBMED REPERENCE AUTHORS TITLE JOURNAL

PRATURBS

gene

g

•	581 GGA		
	218 GlnGl	GlnGlnMetAsnCysGlyMetGlyAsnGluArgAsnGlyValSerLeuGlySerValGly 237	È
	584 GGGTC	OGGICTITITAATGIATATGAGGAATTTCAA	<u>අ</u>
	238 CyeG	lyGluLeuGlnSerLeuSerMetSerMetSerProGlySerGlnSerSerCyeVal 257	à i
٥	620		a 8
_	258 Thral	laProSer 261	s 6
.	668 ACTOC	ACTOGCTCTCACCACCAACAAAACCAAAACCAAAACCACAAAGCCAAAACCACC	3 8
٠.		GlyThrAspSerValAlaval 268	; a
ם			ઠે
ם ג	788 GCGAJ	ASPALALYSLYSTAGSTYKISALALYSLEGGLYGILLYSGLTYGOVALHIS 285 GCGAAGAAGAGGGACAAGAGATGTTGTAGTTGTTGTCAGAAACAGATTGTTGTT GCGAAGAAGAGGGACAAGAGATGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT	qq
> 4	y d	ArgiveSerIleAspThrPheGlyGlnArgThrSerGlnDyrArgGlyValThrArgHis 305	∂ සි
a ;		2 6	ò
۵ م	106 AGAT	Arginintalyagiyedindanibberitpabaraneryybiyedinistoin 323 	۵
ه د	326 ThrA ::: 968 AGTAC	ThrArglysGlykrgGlnValTyrLeuGlyGlyTyrAspMetGluGluLysAlaAlaAlaArg 345 :::	PESSICT 9
> .		m .	
م	1028 GCAT	2	
	366 Gluar 	GlubbntyrglnyalginleuglugiumetlygabnmetSeratgginglutyrvalala 385 gagaattatcagaaagagattgaagacatgagaaacatgactagacaagaatatgtgca 1147	
۵ ۸	386 Histo	HisheuArgArgLysSerSerGlyPheSerArgGlyAlaSerIleTyrArgGlyValThr	
>			
۵	1208 AGAC		
۶ ۷	1268 CTCT	LeuTyrLeuGlyThrPheSerThrGlnGlucluAlaAlacluAlaTyrAspValAlaAla 445 	
>	446 IleL		
ą	1328 ATTA	agtreceregazaaateerereaetaaetitaatateaegagtaegatetreat 1387	
٤:		ArgileMetAlaSerSerAsnLeuLeuAlaGlyGluLeuAlaArgArgLysLysAspAsn 485	
ă	_	7	
≿	486 AspP	AspProArgAsnLysAspIleAspIlyrAsnLysSerValValThrSerValAsnAsnGlu 505	
ጅ ፅ	506 GluT 1466 GAA-	GluthrvalGinValGinAlaGiyAsnAsnAsnAsnGiuAsnAspAspRerGiuTrpLysMet 525 GJA	
>	526 Vall	euPheAsnHisProSerGlnGlnGlnGlnAl	
ą	1469		

ò	546	546 IleMetAgnCysGlyAsnTyrArgAsnSerAlaPheSerMetAlaLeuGlnAspLeuIle 565	265
qq	1478	1478 GCTCTAAATGCT	1489
ó	566	566 GlyileaspSerValGlySerGlyGlnHisAsnMetLeuAspGluSerSerLysIleGly 585	585
dC	1489		1489
È	. 985	ThrHisPheSerAsnThrSerSerLeuValThrSerLeuSerSerArgGluAlaSer	605
q ₀	1490	GTTGTGGAAGGTGGTTCCAACAAGAAGTCGGT 1522	1522
ઠે	909	606 ProGluLysArgGlyProSerLeuLeuPheProMetProProMetGluThrLys 623	623
q	1523	1523 ACTCCCGAGAGACTCTTGAGTTTTCCGGCGATTTTCGCGTTGCCTCAGTTAATCAAAG 1582	1582
ઠે	624	624 Ileval AsnProlleGlyThrSerValThrSerTrpLeuProSerProThrValGln 642	642
dg dg	1583	ATGITCGGATCAAATATGGGCGGAAATATGAGTCCTTGGACATCAAACCCTAATGCTGAG .1642	.1642
ò	643	643 MethrgFroSerProAlaileSerLeuSerHisLeuProValPheAlaSerTrpThrAsp 662	662
Ор	1643	CTTAAGACCGTCGCTCTTACTTTGCCTCAGATGCCGGTTTTCGCTGCTTGGGTGAT	1699
ò	663	663 Thr 663	
q	1700	TCT 1702	
0 1111111			•